David Shaw’s GeneDx Holdings WGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.67M Buy
38,877
+19,974
+106% +$1.14M ﹤0.01% 2952
2026
Q1
$1.21M Buy
18,903
+3,300
+21% +$301K ﹤0.01% 3292
2025
Q4
$2.03M Buy
+15,603
New +$2.14M ﹤0.01% 3040
2025
Q3
Sell
-9,155
Closed -$997K 4965
2025
Q2
$845K Sell
9,155
-390,549
-98% -$30.7M ﹤0.01% 3347
2025
Q1
$35.4M Buy
399,704
+105,187
+36% +$9.13M 0.03% 631
2024
Q4
$22.6M Buy
294,517
+263,126
+838% +$18.4M 0.02% 965
2024
Q3
$1.33M Buy
+31,391
New +$1.06M ﹤0.01% 3051
2023
Q1
Sell
-19,701
Closed -$172K 4914
2022
Q4
$172K Sell
19,701
-7,742
-28% -$171K ﹤0.01% 4276
2022
Q3
$795K Sell
27,443
-65,177
-70% -$2.98M ﹤0.01% 3748
2022
Q2
$3.85M Buy
92,620
+37,014
+67% +$2.51M ﹤0.01% 2444
2022
Q1
$5.63M Buy
55,606
+12,361
+29% +$1.37M 0.01% 2174
2021
Q4
$6.37M Buy
43,245
+773
+2% +$173K 0.01% 2124
2021
Q3
$10.6M Buy
42,472
+6,061
+17% +$2.08M 0.01% 1474
2021
Q2
$16.8M Sell
36,411
-5,370
-13% -$2.31M 0.01% 1114
2021
Q1
$20.5M Buy
+41,781
New +$21.7M 0.02% 914

Other funds holding WGS

David Shaw's WGS Position: Q2 2026 in Review

David Shaw increased its GeneDx Holdings (WGS) stake by 106% in Q2 2026, buying an estimated $1.14M and bringing the position to 38,877 shares worth $2.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2952.

David Shaw first reported a position in WGS in Q1 2021 and has held it in 15 quarters since. The position peaked at $35.4M in Q1 2025. 222 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

  • David Shaw held 38,877 shares of GeneDx Holdings worth $2.67M as of Q2 2026.
  • David Shaw bought 19,974 GeneDx Holdings shares in Q2 2026, an estimated $1.14M.
  • GeneDx Holdings made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2952 holding.
  • David Shaw first reported a position in GeneDx Holdings in Q1 2021 and has held it in 15 quarters since.
  • David Shaw's GeneDx Holdings position peaked at $35.4M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.